Frank L. Karbe's Insider Trades & SAST Disclosures
Frank L. Karbe's most recent trade in Cidara Therapeutics Inc was a trade of 115,000 Employee Stock Option (right to buy) done . Disclosure was reported to the exchange on Feb. 24, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Frank L. Karbe.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Cidara Therapeutics Inc | Frank L. Karbe | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2025 | 115,000 | 115,000 | - | - | Employee Stock Option (right to buy) | |
| Cidara Therapeutics Inc | Frank L. Karbe | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2025 | 57,500 | 57,500 (0%) | 0% | 0 | Common Stock | |
| Phathom Pharmaceuticals Inc | Frank L. Karbe | Director | Purchase of securities on an exchange or from another person at price $ 7.93 per share. | 13 Dec 2024 | 12,500 | 57,000 (0%) | 0% | 7.9 | 99,084 | Common Stock |
| Phathom Pharmaceuticals Inc | Frank L. Karbe | Director | Grant, award, or other acquisition of securities at price $ 10.16 per share. | 29 May 2024 | 25,000 | 44,500 (0%) | 0% | 10.2 | 254,113 | Common Stock |
| Phathom Pharmaceuticals Inc | Frank L. Karbe | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2024 | 17,500 | 17,500 | - | - | Stock Option (Right to Buy) | |
| Phathom Pharmaceuticals Inc | Frank L. Karbe | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2024 | 10,500 | 19,500 (0%) | 0% | 0 | Common Stock | |
| Better Therapeutics Inc | Frank Karbe L. | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2023 | 62,500 | 526,516 | - | 0 | Common Stock | |
| Better Therapeutics Inc | Frank L. Karbe | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 0.73 per share. | 27 Jul 2023 | 137,005 | 429,429 | - | 0.7 | 100,000 | Common Stock |
| Phathom Pharmaceuticals Inc | Frank L. Karbe | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2023 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Phathom Pharmaceuticals Inc | Frank L. Karbe | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2023 | 9,000 | 9,000 (0%) | 0% | 0 | Common Stock | |
| Better Therapeutics Inc | Frank L. Karbe | Director, See Remarks | Purchase of securities on an exchange or from another person at price $ 0.83 per share. | 10 Apr 2023 | 242,424 | 292,424 | - | 0.8 | 200,000 | Common Stock |
| Better Therapeutics Inc | Frank L. Karbe | Director, See Remarks | Purchase of securities on an exchange or from another person at price $ 2.09 per share. | 15 Sep 2022 | 50,000 | 50,000 | - | 2.1 | 104,695 | Common Stock |
| Better Therapeutics Inc | Frank L. Karbe | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jul 2022 | 472,200 | 472,200 | - | - | Stock Option (Right to Buy) | |
| Phathom Pharmaceuticals Inc | Frank L. Karbe | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2022 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Phathom Pharmaceuticals Inc | Frank L. Karbe | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Apr 2022 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges